Juvenile Idiopathic Arthritis
Patients, caregivers weigh disease, treatment risks when deciding to end JIA therapy

Among patients with well-controlled juvenile idiopathic arthritis, and their caregivers, when and how they decide to discontinue treatment likely depends on whether they are more concerned with disease- or treatment-related complications, and often involves a “trade-off” between these competing risks, according to survey findings published in Arthritis Care & Research.
ADA2 levels elevated in systemic JIA with macrophage activation syndrome
Absence of pediatric studies blocking critical biologic DMARDs for JIA
Exposure to TNF inhibitors increases psoriasis risk in children with IBD, JIA
Children with inflammatory bowel disease, juvenile idiopathic arthritis and chronic noninfectious osteomyelitis had an increased rate of psoriasis, and those exposed to tumor necrosis factor inhibitor therapy exhibited the highest risk, according to research presented at the American College of Rheumatology/Association of Rheumatology Professionals annual meeting.
Intervention bundle improves flu vaccination rates in RA/JIA patients
Children with Down syndrome have higher risk for arthritis, delayed diagnosis
Poor health literacy, wait times drive influenza vaccine hesitancy in RA, JIA

ATLANTA — Limited knowledge about inactivated vaccines, misconceptions and fears, as well as long wait times and accessibility issues are among the leading drivers of influenza vaccine hesitancy among adults with rheumatoid arthritis and juvenile idiopathic arthritis, according to a presenter at ACR/ARP 2019.
Psoriasis risk spikes with anti-TNF use in children with inflammatory diseases

Children with either inflammatory bowel disease, chronic noninfectious osteomyelitis or juvenile idiopathic arthritis developed psoriasis at an increased rate compared with the general public, with the highest rates seen among those treated with TNF inhibitors, according to data published in Arthritis Care & Research.